You are here

Repifermin Phase II Study Fails To Meet Primary Endpoint

ROCKVILLE, Md., Sept. 25 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. today reported that a Phase 2 clinical trial of topically administered repifermin (keratinocyte growth factor-2, KGF-2) in adults with chronic venous ulcers did not meet its primary endpoint. Efficacy was measured in the trial as the percentage of patients achieving complete wound closure within 20 weeks of initiating treatment. The percentage of patients treated with repifermin at doses of 60 and 120 mcg per square centimeter of wound area who achieved complete wound closure within the 20-week timeframe was not statistically significantly different from placebo, nor was there any favorable trend for the repifermin-treated groups. The 352 patients who were randomized in the multi-center double-blind placebo-controlled trial had chronic venous ulcers from 3 to 25 square centimeters in size that had persisted unhealed for 3 to 36 months prior to enrollment. All patients received standardized compression therapy and wound care for the duration of the study. Repifermin was well tolerated with a safety profile similar to placebo. There also were no significant differences between repifermin and placebo on prespecified secondary endpoints of time to complete wound closure or complete wound closure by 16 or 26 weeks of treatment.

David C. Stump, M.D., Senior Vice President, Drug Development, said, "Given the prior results with repifermin in this patient population, we are disappointed in the efficacy results from this study. We are especially disappointed for the many patients in need who could benefit from the availability of improved treatment options for this difficult medical problem. However, in my opinion, the level of evidence is now not sufficient to warrant our further development of repifermin for use in the treatment of chronic venous ulcers."

Craig A. Rosen, Ph.D., President, Research and Development, said, "Obviously, we are disappointed in the results of the repifermin trial in chronic venous ulcers. However, Human Genome Sciences has an exceptionally rich development pipeline of novel clinical and advanced preclinical compounds, each of which has a sound biological rationale and addresses a major unmet medical need. The focus of our drug development program continues to be cancer and immunology."

A Phase 2 trial of the use of repifermin for the treatment of cancer therapy-induced mucositis is still ongoing.

For more information on repifermin, see https://www.gsk.com/.

For additional information on Human Genome Sciences, please visit the web site at http://www.hgsi.com/.

Recent Headlines

WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs